Crispr Therapeutics AG vs Enphase Energy Inc — how do they compare? Crispr Therapeutics AG trades at $53.96 (market cap $5.23B), while Enphase Energy Inc trades at $42.7 (market cap $5.59B). The key difference: Crispr Therapeutics AG and Enphase Energy Inc are close in size by market cap. Which is the better fit depends on your goals.
| CRSP | ENPH | |
|---|---|---|
Market Cap | $5.23B | $5.59B |
Sector | Health | Technology |
52-Week High | $76.78 | $72.33 |
52-Week Low | $44.34 | $26.12 |
Enterprise Value | $3.65B | $5.23B |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →